Mountain View, Calif. • 650-386-3100 • www.mappharma.com
Exchange and Ticker: Nasdaq: MAPP
Filing Range: 5M shares @ $14.00 to $16.00
Offering Price: $12.00
Close on First Day: $13.35
Offering Size: $60M
Shares Outstanding: 19,272,409
Underwriters: Merrill Lynch/ Morgan Stanley
Co-managers: Deutsche Bank Securities Corp.
Company Counsel: Latham & Watkins
Manager Counsel: Heller Ehrman LLP
Auditor: Pricewaterhouse Coopers LLP
Market Capitalization on 10/31/07: $267.50M
Close price at current month end: $13.88
COMPANY DESCRIPTION
Develops inhaled drug products. The company’s therapies and inhalation delivery platforms treat a spectrum of respiratory and systemic diseases. MAP’s lead product is a proprietary formulation of budesonide for the treatment of pediatric asthma. Competitors include Merck & Co. Inc., Teva Pharmaceuticals Industries Ltd. and GlaxoSmithKline.
VENTURE BACKERS
Aisling Capital, Alexandria Real Estate Equities, Bain Capital, Bay City Capital, D.E. Shaw Technology Ventures, Pequot Capital Management Inc., Skyline Ventures
Source: Thomson Financial